| Literature DB >> 21803289 |
Andreas L Birkenfeld1, Hui-Young Lee, Fitsum Guebre-Egziabher, Tiago C Alves, Michael J Jurczak, Francois R Jornayvaz, Dongyang Zhang, Jennifer J Hsiao, Alejandro Martin-Montalvo, Antje Fischer-Rosinsky, Joachim Spranger, Andreas F Pfeiffer, Jens Jordan, Martin F Fromm, Jörg König, Stefanie Lieske, Christopher M Carmean, David W Frederick, Dirk Weismann, Felix Knauf, Pablo M Irusta, Rafael De Cabo, Stephen L Helfand, Varman T Samuel, Gerald I Shulman.
Abstract
Reduced expression of the Indy (I'm Not Dead, Yet) gene in D. melanogaster and its homolog in C. elegans prolongs life span and in D. melanogaster augments mitochondrial biogenesis in a manner akin to caloric restriction. However, the cellular mechanism by which Indy does this is unknown. Here, we report on the knockout mouse model of the mammalian Indy (mIndy) homolog, SLC13A5. Deletion of mIndy in mice (mINDY(-/-) mice) reduces hepatocellular ATP/ADP ratio, activates hepatic AMPK, induces PGC-1α, inhibits ACC-2, and reduces SREBP-1c levels. This signaling network promotes hepatic mitochondrial biogenesis, lipid oxidation, and energy expenditure and attenuates hepatic de novo lipogenesis. Together, these traits protect mINDY(-/-) mice from the adiposity and insulin resistance that evolve with high-fat feeding and aging. Our studies demonstrate a profound effect of mIndy on mammalian energy metabolism and suggest that mINDY might be a therapeutic target for the treatment of obesity and type 2 diabetes.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21803289 PMCID: PMC3163140 DOI: 10.1016/j.cmet.2011.06.009
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287